Summary
The NAFTA Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market size (value , and forecast to 2029). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The pharmaceuticals industry within the NAFTA countries had a total market value of $6,28,538.4 million in 2024.The Mexico was the fastest growing country, with a CAGR of 8.4% over the 2020-24 period.
- Within the pharmaceuticals industry, the US is the leading country among the NAFTA bloc, with market revenues of $5,69,333.8 million in 2024. This was followed by Canada and Mexico, with a value of $45,620.4 and $13,584.1 million, respectively.
- The US is expected to lead the pharmaceuticals industry in the NAFTA bloc, with a value of $7,09,520.1 million in 2029, followed by Canada and Mexico with expected values of $57,225.7 and $17,780.6 million, respectively.
Scope
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the NAFTA pharmaceuticals market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA pharmaceuticals market
- Leading company profiles reveal details of key pharmaceuticals market players’ NAFTA operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA pharmaceuticals market with five year forecasts
- Compares data from the US, Canada and Mexico, alongside individual chapters on each country
Reasons to Buy
- What was the size of the NAFTA pharmaceuticals market by value in 2024?
- What will be the size of the NAFTA pharmaceuticals market in 2029?
- What factors are affecting the strength of competition in the NAFTA pharmaceuticals market?
- How has the market performed over the last five years?
- What are the main segments that make up the NAFTA pharmaceuticals market?
'
Table of Contents
1 Introduction
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 NAFTA Pharmaceuticals
2.1. Industry Outlook
3 Pharmaceuticals in Canada
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
4 Macroeconomic Indicators
4.1. Country data
5 Pharmaceuticals in Mexico
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
6 Macroeconomic Indicators
6.1. Country data
7 Pharmaceuticals in The United States
7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis
8 Macroeconomic Indicators
8.1. Country data
9 Company Profiles
9.1. Johnson & Johnson
9.2. Merck & Co Inc
9.3. AbbVie Inc
9.4. Pfizer Inc
9.5. Sinopharm Group Co Ltd
9.6. Shanghai Pharmaceuticals Holding Co Ltd
9.7. CSPC Pharmaceutical Group Ltd
9.8. Takeda Pharmaceutical Co Ltd
9.9. Novartis AG
9.10. AstraZeneca Plc
9.11. GSK plc
9.12. F. Hoffmann-La Roche Ltd
9.13. Sanofi
9.14. Laboratoires Pierre Fabre SA
9.15. Les Laboratoires Servier SAS
9.16. Ipsen SA
9.17. Bayer AG
9.18. Boehringer Ingelheim International GmbH
9.19. Fresenius Medical Care AG & Co KGaA
9.20. Merck KGaA
9.21. CSL Ltd
9.22. Ramsay Health Care Ltd
9.23. Mayne Pharma Group Ltd
9.24. Ache Laboratorios Farmaceuticos SA
9.25. EMS SA
9.26. Hypera SA
9.27. Eurofarma Laboratorios SA
9.28. Apotex Inc
9.29. Bausch Health Companies Inc
9.30. Jiangsu Hengrui Pharmaceuticals Co Ltd
9.31. Sun Pharmaceutical Industries Ltd
9.32. Lupin Ltd
9.33. Cipla Ltd
9.34. Dr. Reddy's Laboratories Ltd
9.35. PT Kimia Farma Tbk
9.36. PT Kalbe Farma Tbk
9.37. PT Tempo Scan Pacific Tbk
9.38. A. Menarini Industrie Farmaceutiche Riunite Srl
9.39. Recordati SpA
9.40. Chiesi Farmaceutici SpA
9.41. Astellas Pharma Inc
9.42. Daiichi Sankyo Co Ltd
9.43. Otsuka Holdings Co Ltd
9.44. Genomma Lab Internacional SAB de CV
9.45. Pharmstandard
9.46. Binnopharm Group
9.47. OTC Pharma International BV
9.48. H. Lundbeck AS
9.49. Novo Nordisk AS
9.50. Aspen Pharmacare Holdings Ltd
9.51. Adcock Ingram Holdings Ltd
9.52. Chong Kun Dang Pharmaceutical Corp.
9.53. Hanmi Pharmaceuticals Co Ltd
9.54. Celltrion Inc
9.55. Yuhan Corp
9.56. Almirall SAS
9.57. Grifols SA
9.58. Laboratorios Farmaceuticos Rovi SA
9.59. Abdi Ibrahim Ilac Sanayi ve Ticaret AS
9.60. Deva Holding AS
10 Appendix
10.1. Methodology
10.2. About MarketLine
List of Tables
Table 1: NAFTA countries pharmaceuticals industry, revenue ($m), 2020-29
Table 2: NAFTA countries pharmaceuticals industry, revenue ($m), 2020-24
Table 3: NAFTA countries pharmaceuticals industry forecast, revenue ($m), 2024-29
Table 4: Canada pharmaceuticals market value: $ million, 2019-24
Table 5: Canada pharmaceuticals market category segmentation: % share, by value, 2019-24
Table 6: Canada pharmaceuticals market category segmentation: $ million, 2019-24
Table 7: Canada pharmaceuticals market geography segmentation: $ million, 2024
Table 8: Canada pharmaceuticals market value forecast: $ million, 2024-29
Table 9: Canada Size of Population (Million), 2020-24
Table 10: Canada Real GDP (Constant 2010 Prices, $ Billion), 2020-24
Table 11: Canada GDP (Current Prices, $ Billion), 2020-24
Table 12: Canada Inflation, 2020-24
Table 13: Canada Consumer Price Index (Absolute), 2020-24
Table 14: Canada Exchange Rate, 2019-24
Table 15: Mexico pharmaceuticals market value: $ million, 2019-24
Table 16: Mexico pharmaceuticals market category segmentation: % share, by value, 2019-24
Table 17: Mexico pharmaceuticals market category segmentation: $ million, 2019-24
Table 18: Mexico pharmaceuticals market geography segmentation: $ million, 2024
Table 19: Mexico pharmaceuticals market value forecast: $ million, 2024-29
Table 20: Mexico Size of Population (Million), 2020-24
Table 21: Mexico Real GDP (Constant 2010 Prices, $ Billion), 2020-24
Table 22: Mexico GDP (Current Prices, $ Billion), 2020-24
Table 23: Mexico Inflation, 2020-24
Table 24: Mexico Consumer Price Index (Absolute), 2020-24
Table 25: Mexico Exchange Rate, 2019-24
Table 26: United States pharmaceuticals market value: $ million, 2019-24
Table 27: United States pharmaceuticals market category segmentation: % share, by value, 2019-24
Table 28: United States pharmaceuticals market category segmentation: $ million, 2019-24
Table 29: United States pharmaceuticals market geography segmentation: $ million, 2024
Table 30: United States pharmaceuticals market value forecast: $ million, 2024-29
Table 31: United States Size of Population (Million), 2020-24
Table 32: United States Real GDP (Constant 2010 Prices, $ Billion), 2020-24
Table 33: United States GDP (Current Prices, $ Billion), 2020-24
Table 34: United States Inflation, 2020-24
Table 35: United States Consumer Price Index (Absolute), 2020-24
Table 36: United States Exchange Rate, 2019-24
List of Figures
Figure 1: NAFTA countries pharmaceuticals industry, revenue ($m), 2020-29
Figure 2: NAFTA countries pharmaceuticals industry, revenue ($m), 2020-24
Figure 3: NAFTA countries pharmaceuticals industry forecast, revenue ($m), 2024-29
Figure 4: Canada pharmaceuticals market value: $ million, 2019-24
Figure 5: Canada pharmaceuticals market category segmentation: $ million, 2019-24
Figure 6: Canada pharmaceuticals market geography segmentation: % share, by value, 2024
Figure 7: Canada pharmaceuticals market value forecast: $ million, 2024-29
Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2024
Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2024
Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2024
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2024
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2024
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2024
Figure 14: Mexico pharmaceuticals market value: $ million, 2019-24
Figure 15: Mexico pharmaceuticals market category segmentation: $ million, 2019-24
Figure 16: Mexico pharmaceuticals market geography segmentation: % share, by value, 2024
Figure 17: Mexico pharmaceuticals market value forecast: $ million, 2024-29
Figure 18: Forces driving competition in the pharmaceuticals market in Mexico, 2024
Figure 19: Drivers of buyer power in the pharmaceuticals market in Mexico, 2024
Figure 20: Drivers of supplier power in the pharmaceuticals market in Mexico, 2024
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2024
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2024
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2024
Figure 24: United States pharmaceuticals market value: $ million, 2019-24
Figure 25: United States pharmaceuticals market category segmentation: $ million, 2019-24
Figure 26: United States pharmaceuticals market geography segmentation: % share, by value, 2024
Figure 27: United States pharmaceuticals market value forecast: $ million, 2024-29
Figure 28: Forces driving competition in the pharmaceuticals market in the United States, 2024
Figure 29: Drivers of buyer power in the pharmaceuticals market in the United States, 2024
Figure 30: Drivers of supplier power in the pharmaceuticals market in the United States, 2024
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2024
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2024
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2024
